Pharma: Page 5
-
Courtesy of Merck
Half of Merck’s sales are in jeopardy. Can Keytruda’s sequel save the day?
Wall Street analysts expect the subcutaneous version of Keytruda, which just launched last week, to help soften the blow when the original loses patent protection later this decade.
By Michael Gibney • Oct. 2, 2025 -
Jacob Bell/BioPharma Dive
Takeda, in reversal, abandons cell therapy research
The Japanese pharmaceutical company, which had made cell therapy a priority a few years ago, aims to partner its work while prioritizing investments elsewhere.
By Delilah Alvarado • Oct. 1, 2025 -
Explore the Trendline➔
National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
TrendlineAlzheimer's disease
Many companies hope to follow in the footsteps of Biogen, Eisai and Eli Lilly by developing new therapies for the debilitating disease, which affects tens of millions of people and costs healthcare systems hundreds of billions of dollars each year.
By BioPharma Dive staff -
ASCO / Nick Agro
The top biopharma conferences in 2026
Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ research progress. Here’s a list of conferences to watch next year.
By Ben Fidler • Oct. 1, 2025 -
Win McNamee via Getty Images
Trump administrationTrump, Pfizer drug pricing deal short on details, possible impact
A pact to offer “most favored nation” prices to state Medicaid programs and via direct-to-consumer channels doesn’t affect those on commercial insurance or who won’t pay out of pocket.
By Jonathan Gardner • Sept. 30, 2025 -
Getty Images
Obesity drugsMetsera strengthens case for Pfizer buyout with latest study data
In a Phase 2 trial, a drug at the center of the $4.9 billion deal matched the type of weight loss trajectory seen in testing of Eli Lilly’s Zepbound.
By Jonathan Gardner • Sept. 30, 2025 -
Courtesy of GSK Flickr page
Emma Walmsley, big pharma’s first female CEO, to depart GSK
Walmsley, who helped push GSK to focus more exclusively on specialty medicines and oncology, will be succeeded by commercial head Luke Miels on Jan. 1.
By Jonathan Gardner • Sept. 29, 2025 -
Courtesy of Genmab A/S
Genmab to acquire closely watched cancer drug in $8B Merus buyout
The deal hands Genmab a drug that showed the potential in earlier testing to extend survival in head and neck cancer when added to Merck’s widely used immunotherapy Keytruda.
By Delilah Alvarado • Sept. 29, 2025 -
Getty Images
Pharma reshoringKey exemptions could limit impact of Trump’s pharmaceutical tariffs
Carve-outs for generics, European exports and companies onshoring drug production will likely shield most branded drugs from the 100% levies Trump announced Thursday.
By Jonathan Gardner • Sept. 26, 2025 -
Andrew Harnik via Getty Images
Pharma reshoringTrump sets tariffs on pharmaceuticals, trucks, furniture
The new levies, ranging from 25% to 100%, will go into effect Oct. 1, the president said Thursday.
By Phil Neuffer • Sept. 25, 2025 -
Scott Olson via Getty Images
Lilly’s oral SERD gets FDA nod in advanced breast cancer
The clearance of Inluriyo is another development among a group of oral medicines aiming to supplant a widely used, injectable type of hormone therapy.
By Ben Fidler • Sept. 25, 2025 -
Scott Olson via Getty Images
Obesity drugsLilly stops trial of muscle-sparing obesity drug
Lilly’s decision comes as the FDA has indicated potentially higher approval standards for drugs meant to preserve muscle in people taking weight loss medicines.
By Jonathan Gardner • Sept. 25, 2025 -
Courtesy of Sanofi
Emerging biotechSanofi Ventures banks $625M to back young biotechs, digital health startups
The French pharma’s venture arm will use the funds to back companies working in immunology, neurology, rare diseases and vaccines.
By Gwendolyn Wu • Sept. 24, 2025 -
Getty Images
Trump administrationFDA, in unusual step, aims to repurpose old GSK drug as autism treatment
After reviewing existing published literature, the agency initiated the approval of Wellcovorin — which GSK stopped selling more than two decades ago — for a condition associated with autism.
By Kristin Jensen • Sept. 23, 2025 -
Jacob Bell/BioPharma Dive
Obesity drugsPfizer buys back into obesity drug chase with $4.9B Metsera deal
The deal ends a short run as a publicly traded company for Metsera, which is being sold for more than double its IPO price amid enthusiasm for its weight loss medicines.
By Jonathan Gardner • Sept. 22, 2025 -
Elijah Nouvelage / Stringer via Getty Images
VaccinesCDC panel recommends splitting measles, varicella shots
The committee reconvened Friday to re-do a vote on coverage of the combined MMRV shot through the Vaccines for Children program, citing panelists’ confusion the day before.
By Jonathan Gardner • Updated Sept. 19, 2025 -
Getty Images
Pharma reshoring
GSK ups US investment with $30B spending plan
The British drugmaker’s commitment comes as some of its pharma peers question their U.K. presence amid a widening row there over pricing polices.
By Ned Pagliarulo • Sept. 17, 2025 -
Getty Images
News roundupLilly, Novo showcase new obesity drug data; Fasenra falls short in COPD
Lilly claimed success in a head-to-head trial of oral GLP-1 drugs. Elsewhere, Novo planned a new weight loss trial and an AI-focused startup raised its second “megaround.”
By BioPharma Dive staff • Sept. 17, 2025 -
wirestock via envato
Sponsored by AltorWorking smarter: best practices for thermal modeling in cold chain packaging design
Smarter cold chain design starts with thermal modeling—learn best practices here.
Sept. 15, 2025 -
Getty Images
Emerging biotechLilly to give biotech startups access to AI tools
Insitro, Firefly Bio and Superluminal Medicines are among the first participants in Lilly’s “TuneLabs” platform, which the pharma says can help young drugmakers while training its own models.
By Gwendolyn Wu • Sept. 9, 2025 -
Getty Images
Novartis to gain heart drug in $1.4B deal for Tourmaline Bio
Tourmaline recently unveiled mid-stage trial data for its anti-inflammatory drug, which is ready for Novartis to advance into Phase 3 testing for heart disease.
By Delilah Alvarado • Sept. 9, 2025 -
Jens Schlueter via Getty Images
VaccinesPfizer, BioNTech showcase new data supporting COVID booster
The companies said their updated shot spurred an increase in neutralizing antibodies against currently circulating strains, answering calls for more corroborating evidence.
By Delilah Alvarado • Sept. 8, 2025 -
Getty Images
News roundup
Amgen to invest $600M in new US center; Sanofi drug for ITP approved
The new "science and innovation center" will be built at Amgen's headquarters in Thousand Oaks, California. Elsewhere, Wayrilz became the first BTK blocker cleared for immune thrombocytopenia.
By BioPharma Dive staff • Sept. 2, 2025 -
Getty Images
News roundup
Amylyx drug comes up short; Sanofi names new CMO
AMX0035 missed the goals of a study in progressive supranuclear palsy. Elsewhere, Novartis and BioArctic struck a deal, and Genentech started building its first East Coast factory.
By BioPharma Dive staff • Aug. 27, 2025 -
Scott Olson via Getty Images
Obesity drugs
Lilly to submit obesity pill after hitting goal in third late-stage trial
In people with diabetes and obesity, orforglipron led to weight loss near what people without diabetes experienced in prior testing.
By Jonathan Gardner • Aug. 26, 2025 -
Getty Images
News roundup
FDA cancels adcomm on Biohaven drug; Catalent lays off staff
Analysts found the agency's decision to cancel the meeting encouraging. Elsewhere, the Novo Holdings-owned CDMO cut about 350 staff at a gene therapy facility.
By BioPharma Dive staff • Aug. 22, 2025
Previous
